GlassScriptPhysician profile
Jennifer Taylor
NPI 1609397835
$2,155.07
in general payments reported to CMS, 2019-2025
24 companies · $191 in 2025
The $191 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $330 · 2022: $505 · 2023: $811 · 2024: $318 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,235 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,234.87 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $442.20 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $200.05 | 2021-2024 | Rexulti, Abilify Maintena |
| Novo Nordisk INC | $183.63 | 2021-2023 | Rybelsus, Ozempic |
| Astellas Pharma US INC | $159.10 | 2022-2023 | Veozah, Myrbetriq |
| Lilly USA, LLC | $144.60 | 2021-2023 | Mounjaro, Trulicity |
| Neurocrine Biosciences, INC. | $127.47 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $124.93 | 2021 | |
| Amgen INC. | $98.02 | 2021-2023 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $93.95 | 2021-2023 | Farxiga |
| Boston Scientific Corporation | $88.47 | 2022-2025 | Watchman Flx |
| Pfizer INC. | $86.28 | 2021-2024 | |
| Sanofi Pasteur INC. | $72.27 | 2022-2023 | |
| Mylan Specialty L.P. | $47.73 | 2023-2024 | Yupelri |
| Idorsia Pharmaceuticals US INC | $46.33 | 2022-2023 | Quviviq |
| Glaxosmithkline, LLC. | $42.54 | 2023-2024 | Trelegy Ellipta, Shingrix |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $39.64 | 2023-2024 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $30.63 | 2025 | Dupixent |
| Teva Pharmaceuticals USA, INC. | $25.79 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.51 | 2022 | |
| Biogen, INC. | $16.77 | 2021 | |
| Almatica Pharma LLC | $15.95 | 2022 | |
| Currax Pharmaceuticals LLC | $15.15 | 2023 | Contrave |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.60 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.46 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.